Overview

A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B

Status:
RECRUITING
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of combined/uncombined nucleoside (acid) analogues of TQA3810 tablets.
Phase:
PHASE2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.